The Rationale for the Phase I TRANSCEND NHL 001 Trial

Video

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the rationale for phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory large B-cell lymphoma, which were presented at the 2019 American Society of Hematology Annual Meeting.

TRANSCEND-NHL 001 was launched to serve an unmet medical need for new treatment options in this patient population. Conventional therapies have a low single-agent response rate, no chance of cure, and median overall survival of 6 month or less in these patient. The hope was that liso-cel would improve outcomes and quality of life in these patients, says Abramson.

For more about the TRANCEND-NHL 001 trialhttps://www.targetedonc.com/news/fda-grant-priority-review-to-lisocel-in-relapsedrefractory-large-bcell-lymphoma

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content